666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Sarah P. Blagden(Churchill Hospital), David J. Harrison(NHS Lothian), T.R. Jeffry Evans(Leiden University Medical Center), Mustafa Elshani(University of St Andrews), Fiona G. McKissock(Nucana (United Kingdom)), A. Skolariki(Churchill Hospital), Alison L. Dickson(University of St Andrews), I.H. Um(University of St Andrews), R. Plummer(Northern Health and Social Care Trust), Zhuang Boh(Edinburgh Cancer Research), N. Cook(The Christie NHS Foundation Trust), J. Bloss(Nucana (United Kingdom)), Ying Zhang(Boston Children's Hospital), S.N. Symeonides(Edinburgh Cancer Research), Noor R. Md. Haris(Newcastle upon Tyne Hospitals NHS Foundation Trust), Elisabeth Oelmann(Nucana (United Kingdom))
Cited by 3
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
High-frequency developmental abnormalities in p53-deficient mice
|Current Biology|1995|467
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
|Journal of Clinical Oncology|2018|274
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222